Kaneka’s Floradapt Cardio probiotic formulation achieved Health Canada approval
Kaneka Americas Holdings Inc. has achieved Health Canada Class III approval for Floradapt Cardio under the Natural Health Products Directorate
Photo © Shutterstock.com/AlexLMX
Kaneka Americas Holdings Inc. (Newark, CA) has achieved Health Canada Class III approval for Floradapt Cardio under the Natural Health Products Directorate. The product is identified by the Natural Product Number (NPN) 80096187.
“With this approval from Health Canada, we are providing dietary supplement companies an innovative way to engage the cardiovascular market,” said Mike Kolifrath, vice president, sales and marketing for Kaneka’s probiotics division, in a press release.
The NPN allows Floradapt Cardio to carry the following claims in Canada:
• Helps to reduce levels of total cholesterol in men and women with hypercholesterolemia.
• Helps support healthy cholesterol level in hypercholesterolemic patients
• Supports cardiovascular health by contributing to healthy serum cholesterol in hypercholesterolemic patients
• Helps support intestinal / gastrointestinal health
• Could promote a favorable gut flora
• Source of probiotics
The NPN for Floradapt Cardio is one of a number of regulatory milestones for Kaneka’s line of probiotics. Prior to this, Kaneka announced self-affirmed GRAS status for its Baby Colic and Intensive G.I. probiotic formulations.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.
